All that glitters is not gold: The need to consider desirable and undesirable immune aspects of oncolytic virus therapy

Derek R. Clements; Youra Kim; Shashi A. Gujar; Patrick W.K. Lee

doi:10.1080/2162402X.2015.1057674

All that glitters is not gold: The need to consider desirable and undesirable immune aspects of oncolytic virus therapy

Derek R. Clements, Youra Kim, Shashi A. Gujar, Patrick W.K. Lee

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

8 Citas (Scopus)

Resumen

Oncolytic viruses (OVs), a novel class of anticancer therapeutic agents, can overturn cancer-mediated immunosuppression and initiate antitumor immunity. Contrary to this paradigm, our recent study illustrates that oncolytic reovirus transiently augments cancer-associated immunosuppression immediately following its therapeutic administration. To achieve the optimum efficacy for OV-based anticancer therapies, the pathophysiological as well as clinical implications of this phenomenon need to be considered.

Idioma original	English
Publicación	OncoImmunology
Volumen	5
N.º	1
DOI	https://doi.org/10.1080/2162402X.2015.1057674
Estado	Published - 2016

Nota bibliográfica

Publisher Copyright:
© 2016 Taylor & Francis Group, LLC.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology

PubMed: MeSH publication types

Journal Article

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1080/2162402X.2015.1057674

Otros archivos y enlaces

Citar esto

@article{b4754416d38e45398a4b76eeb1decce3,

title = "All that glitters is not gold: The need to consider desirable and undesirable immune aspects of oncolytic virus therapy",

abstract = "Oncolytic viruses (OVs), a novel class of anticancer therapeutic agents, can overturn cancer-mediated immunosuppression and initiate antitumor immunity. Contrary to this paradigm, our recent study illustrates that oncolytic reovirus transiently augments cancer-associated immunosuppression immediately following its therapeutic administration. To achieve the optimum efficacy for OV-based anticancer therapies, the pathophysiological as well as clinical implications of this phenomenon need to be considered.",

author = "Clements, {Derek R.} and Youra Kim and Gujar, {Shashi A.} and Lee, {Patrick W.K.}",

note = "Publisher Copyright: {\textcopyright} 2016 Taylor & Francis Group, LLC.",

year = "2016",

doi = "10.1080/2162402X.2015.1057674",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - All that glitters is not gold

T2 - The need to consider desirable and undesirable immune aspects of oncolytic virus therapy

AU - Clements, Derek R.

AU - Kim, Youra

AU - Gujar, Shashi A.

AU - Lee, Patrick W.K.

PY - 2016

Y1 - 2016

N2 - Oncolytic viruses (OVs), a novel class of anticancer therapeutic agents, can overturn cancer-mediated immunosuppression and initiate antitumor immunity. Contrary to this paradigm, our recent study illustrates that oncolytic reovirus transiently augments cancer-associated immunosuppression immediately following its therapeutic administration. To achieve the optimum efficacy for OV-based anticancer therapies, the pathophysiological as well as clinical implications of this phenomenon need to be considered.

AB - Oncolytic viruses (OVs), a novel class of anticancer therapeutic agents, can overturn cancer-mediated immunosuppression and initiate antitumor immunity. Contrary to this paradigm, our recent study illustrates that oncolytic reovirus transiently augments cancer-associated immunosuppression immediately following its therapeutic administration. To achieve the optimum efficacy for OV-based anticancer therapies, the pathophysiological as well as clinical implications of this phenomenon need to be considered.

UR - http://www.scopus.com/inward/record.url?scp=84954453434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954453434&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1057674

DO - 10.1080/2162402X.2015.1057674

M3 - Article

C2 - 26942069

AN - SCOPUS:84954453434

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 1

ER -

All that glitters is not gold: The need to consider desirable and undesirable immune aspects of oncolytic virus therapy

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto